Deja Moo: The feeling that you've heard this bull before.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess this mornings PR did not have enough substance to initiate a Bullish reaction at the opening. I think they are heading in the right direction it's just that instant gradification makes you feel so good. Maybe it will stir up some GREEN action later in the day.
I see somthing I like and that's GREEN. Is this a beginning of a possible BULL run? I have waited (and it has been hard) for SFNN to finally make it's GREEN turn. I hope this is a start to something good.
Discovery rallys late in day for -.03 loss with a volume of 675,321.
I absolutely agree with you, unfortuately bumpy rides are ahead until full faith is restored. For the ones with faith a big win is ahead. Things will stabilize the price will go up and the SEC filings will occur.
They need a spell check but it is pretty.
Site Navigator
Home
Opportunities
Wholesale Brokers
Apply for a Loan
Intranet Login
fccn is still the most read board today:
Most Read Boards Today
Rank Board Reads
1 Franchise Capital Corp. (FCCN) 73297
2 CyberKey Solutions (CKYS) 46774
3 U. S. Sustainable Energy Corp (USSE) 40189
4 Blackout Media Corp (BKMP)
Back from you 3 day appearance at Club Matt!!!!
fccn over the million share mark!!!
GO GREEN! GO TEAM AERO!!!!
FYI: We are still the most read board.
Most Read Boards Today
Rank Board Reads
1 Franchise Capital Corp. (FCCN) 18394
2 U. S. Sustainable Energy Corp (USSE) 15643
The volume will pick up as we get closer to .04. I think a large majority of the investors own the stock around that number. As we get closer so will the excitement. There's nothing better than GREEN!!
Yea, I guess your right, George Bush isn't loved as a President.
What we really need is George Bush holding an AERO Muffler saying it meets his criteria of the new energy plan... That would make a great PR! GO GREEN!!! GO TEAM AERO!!!
Discovery down .11 on no news but high volume of 1,253,011 shares traded. The rollercoaster continues.
Volume high on no news 292,000 shares traded. up today .007 for a close of .o27
FYI, fccn was the most read board today with 74,067 reads #2 followed way behind with 42,929 reads.
And with no retreats the big volume will come back.. Most of today fccn was in the green and it was a good feeling. it was also a good last chance to get some more of the .02xx shares. I loaded up some more of thoses cheap shares and brought my PPS down.
You sure have that one right...
Patience is a virtue and it often requires more than one day. Your first post was only yesterday and already you are the expert. You say you have been tracking this stock for 2 months yet you have been a memeber of this board for less. GO AWAY!!! I am glad several of your posts have already been deleated. I'm playing my cards with fccn I hope they ban you from this site.
Great News!!
According to American Bulls (Ha! Ha!) a $100 investment into fccn on february 8 2005 would be worth $22,779 if you followed there plan and sold on January 9, 2007!! They haven't posted today's results yet.
It can go up 8.77% every day as far as i'm concerned.. And the best part is it's GrEeN!!! GREEN! It's my favorite color.
If the share dump had not occured I would guess to say that the volume would probably be in the 30m + range and the stock would have passed .10 and we'd be calling everybody and telling them that we already made $10,000 or more from this .04 stock that we bought. In otherwords everybody's your friend when your #1 and your nobody when you lose.
Some of you guys (bashers) need to take a chill pill!!!
Some people say the cup is half full and others say it's half empty... Let's look at the positive side, The mega-dump seems to have ended and were getting back on track and we have been in the green most of the day. It even looks like we will see a green finish today!! Yea the volume is off thanks to the dumper but that will return as the stock starts to drive again.. We know some exciting PR's are gonna hit this week and get this stock moving. In the meantime this may be the last chance to suck in a few more of those super cheap shares. I predict by friday everybody will be singing a different tune about how savvy they were to by this stock at such a bargain basement price. I for one will start to polish up my 1974 chevy vega and get it ready for sale because I'm gonna ride this baby out and make a really big pile of money!!! That's right I'm gonna get me a new car like a Dodge Dart or a slick Chevy Nova and I'm stickin an AERO exhaust on that babY!!
newpontiac -
18 posts and you still haven't bought? what are you waiting for? I don't think it's gonna get cheaper. I wish that I could have initially gotten in at .02xx. I think it's upward an onward from this moment on out. As far as .02xx I don't think we will ever see that again. As far as the stock is concerned I think it's gotta be one of the few "safe" plays in pennyland.
I don't think fccn was in the green at all yesterday. I've got a good feeling about today.... I can smell green in the air!!!. I just jumped in and bought more shares through ameritrade.. I think it's upward and onward again..
fridays 14a
Only stockholders of record at the close of business on January , 2007 are entitled to vote at the Meeting. The Company's common stock is its only class of voting securities. As of January 9, 2007, the Company has 920,558,174 shares of common stock issued and outstanding. Of this amount 780,678,923 shares are held in an escrow account for the benefit of Golden Gate Investors, Inc. and are voted by the Company’s Board of Directors.
This would leave 139,879,251 outstanding.
less GG's 60,000,000 that were not escrowed (I,m guessing here.)
This leaves 79,879,251 shares. Isn't that number around what people had thought the float was? If this is correct the numbers add up..
Discovery up .10 on good news today. volume 3,936,830. DSCO closed at $2.65
If Golden Gate was liquidating these shares then it would answer a lot of the questions. I was absolutely convinced in my mind over the weekend that somebody was dumping a lot of shares because the MM argument did not make sense to me to make this big of an effect. Hopefully they are almost through moving the shares. For a lot of people who had faith this is a one last gift to get some really cheap shares. The price should then correct itself and go to the levels I expected. The news was too good on friday for the price to have dropped it just didn't make sense.
*DJ Discovery Labs Upped To Neutral Vs Sell At Pacific Growth
01/22/2007
Dow Jones News Services
(Copyright © 2007 Dow Jones & Company, Inc.)
(END) Dow Jones Newswires
01-22-07 1431ET
Discovery Press Release
Discovery Labs and FDA Reach Clarity On Path Towards Surfaxin RDS
Approval
Conference Call Scheduled for Today At 11:00 AM EST
WARRINGTON, Pa., Jan. 22, 2007 (PRIME NEWSWIRE) -- Discovery
Laboratories, Inc. (Nasdaq:DSCO) announced today that it has received
guidance from the U.S. Food and Drug Administration (FDA) in a recent
meeting regarding the key remaining steps necessary for potential
approval of Surfaxin(r) (lucinactant) for the prevention of Respiratory
Distress Syndrome (RDS) in premature infants. The guidance provides the
clarity and the defined pathway that Discovery believes is necessary to
address key remaining issues identified in the April 2006 FDA
Approvable Letter. Discovery anticipates filing its formal response to
the Approvable Letter in September or October 2007, followed by a
six-month review cycle by the FDA for potential approval of its New
Drug Application (NDA) for Surfaxin.
The guidance was based on a face-to-face meeting with the FDA on
December 21, 2006 as well as the FDA's review of the meeting briefing
package submitted by Discovery on September 28, 2006.
* The defined pathway to potential Surfaxin approval does not
include a requirement for additional clinical trials.
* The April 2006 Approvable Letter primarily focused on the
Chemistry, Manufacturing and Controls (CMC) section of the
Surfaxin NDA and requested additional information predominantly
involving drug product specifications and related controls.
With the clarity gained at the FDA meeting, Discovery expects
to provide all of the necessary additional information in its
formal response to the Approvable Letter.
* Discovery provided information to the FDA regarding its
comprehensive investigation and remediation of the April 2006
Surfaxin process validation stability failure including the
identification of a most probable root cause. The comprehensive
investigation focused on analysis of manufacturing processes;
analytical methods and method validation; and active
pharmaceutical ingredient suppliers.
Consistent with Discovery's proposal included in the FDA meeting
briefing package, Discovery is planning to initiate the
manufacture of new Surfaxin process validation batches this week
and will submit six months of related stability data in its
forthcoming formal response to the Approvable Letter.
Additionally, the FDA indicated that Surfaxin shelf-life will be
determined based upon comparative stability data from historical
Surfaxin batches, including previously manufactured clinical,
technology transfer, and investigational batches, as well as the
new process validation batches.
Robert J. Capetola, Ph.D., President and Chief Executive Officer of
Discovery, commented, "The encouraging outcome of this important FDA
meeting is a reflection of the leadership and efforts of our team of
regulatory, manufacturing and quality executives. This executive team
is also responsible for improving and enhancing the manufacturing
operations that we acquired from our then contract manufacturer. With
the clarity gained from the FDA meeting, the top priorities now are
completing the necessary work to submit our response to the FDA for
Surfaxin approval, and advancing Aerosurf(tm), our aerosolized
surfactant therapy, into Phase 2 clinical trials."
Conference Call Details
Discovery will hold a conference call today at 11:00 AM EST to further
discuss the foregoing. The call in number is 866-332-5218. The
international call in number is 706-679-3237. This audio webcast will
be available to shareholders and interested parties through a live
broadcast on the Internet at http://audioevent.mshow.com/319609 and
www.discoverylabs.com. The replay number to hear the conference call is
800-642-1687 or 706-645-9291. The passcode is 6538198.
About Surfaxin(r) and RDS
Surfaxin is a precision-engineered, peptide-containing, synthetic
surfactant that is designed to closely mimic the function of natural
human lung surfactant and represents a potential alternative to
animal-derived surfactants. Surfaxin's precision-engineered and
non-immunogenic nature allows it to be further developed as a
therapeutic addressing other pulmonary conditions in neonatal and
pediatric medicine. Data from Discovery's pivotal, multinational SELECT
study demonstrate that Surfaxin is significantly more effective in the
prevention of RDS and improved survival (continuing through at least
one year of life) and other outcomes versus comparator surfactants. The
SELECT and STAR (a supportive Phase 3 study) trials, as well as a
pooled Phase 3 analysis, have been presented at several international
medical meetings and the results from the two studies were published in
Pediatrics.
RDS afflicts approximately 120,000 premature infants in the United
States each year, with a global at-risk population in excess of 500,000
infants. Approximately 75,000 infants are treated annually in the
United States with currently-available surfactant products, all of
which are animal-derived.
DISCLOSURE NOTICE: The information in this press release includes
certain "forward-looking" statements relating to, among other things,
the remaining steps necessary for FDA approval of Surfaxin for the
prevention of RDS in premature infants, including information to be
prepared for inclusion in Discovery's formal response to the second
Approvable Letter and the potential results of Discovery's ongoing
manufacturing investigation and remediation. Although Discovery is
encouraged by its meeting with the FDA and the findings of its
comprehensive investigation to date, both the development of
information for the formal response to the second Approvable Letter and
the comprehensive investigation are ongoing and the final results of
both these efforts could vary materially from the indications obtained
to date. Discovery currently believes that it will succeed in
submitting its complete response to the second Approvable Letter,
including six months of stability data for the new process validation
batches, within the indicated time frame, subject, however, to a
variety of risks, including that Discovery may not succeed in
developing the information necessary for the formal response, the new
process validation batches may fail to meet designated stability or
other release parameters and the final comprehensive investigation
report may identify unforeseen problems that have not yet been
discovered. The reader of this release should understand that the
failure to develop all necessary information required to respond to the
second Approvable letter or to satisfactorily investigate and remediate
Discovery's manufacturing issues could result in significant delays or
additional requirements and potentially prevent the approval of
Surfaxin or other Discovery products.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing
Surfactant Replacement Therapies (SRT) for respiratory diseases.
Surfactants are produced naturally in the lungs and are essential for
breathing. Discovery's technology produces a precision-engineered
surfactant that is designed to closely mimic the essential properties
of natural human lung surfactant. Discovery believes that its
proprietary SRT pipeline has the potential to advance respiratory
medicine and address a variety of respiratory diseases affecting
premature infants, children and adults.
Discovery's lead product candidate, Surfaxin(r), is the subject of an
Approvable Letter from the FDA for the prevention of Respiratory
Distress Syndrome in premature infants. Surfaxin is also being
developed for the prevention and treatment of Bronchopulmonary
Dysplasia in premature infants. Aerosurf(tm), Discovery's aerosolized
SRT, is being developed initially to treat premature infants suffering
from respiratory disorders and is intended to obviate the need for
intubation and conventional mechanical ventilation. Discovery's SRT
pipeline also includes programs addressing Acute Lung Injury, Acute
Respiratory Failure, Cystic Fibrosis, Acute Respiratory Distress
Syndrome, and other respiratory conditions. For more information,
please visit our corporate website at www.Discoverylabs.com.
To the extent that statements in this press release are not strictly
historical, including statements as to business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
financial conditions, the success of Discovery's product development,
or otherwise as to future events, all such statements are
forward-looking, and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from
the statements made. Among the factors which could affect Discovery's
actual results and could cause results to differ from those contained
in these forward-looking statements are the risk that financial
conditions may change, risks relating to the progress of Discovery's
research and development, the risk that Discovery will not be able to
raise additional capital or enter into additional collaboration
agreements (including strategic alliances for Surfactant Replacement
Therapies), the risk that Discovery will not be able to develop or
otherwise provide for a successful sales and marketing organization in
a timely manner, if at all, the risk that approval by the FDA or other
health regulatory authorities of any applications filed by Discovery
may be withheld, delayed and/or limited by indications or other label
limitations, the risk that any such regulatory authority will not
approve the marketing and sale of a drug product even after acceptance
of an application filed by Discovery for any such drug product, risks
that the Chemistry, Manufacturing and Controls (CMC) section of
Discovery's New Drug Application will not satisfy the FDA, risk in the
FDA or other regulatory agency review process generally, risks relating
to the ability of Discovery or Discovery's third party contract
manufacturers and development partners to manufacture or provide
Discovery with adequate supplies of drug substance, drug products and
expertise for completion of any of Discovery's clinical studies, risks
relating to drug manufacturing by Discovery, risks relating to the
integration of manufacturing operations into Discovery's existing
operations, other risks relating to the lack of adequate supplies of
drug substance and drug product for completion of any of Discovery's
clinical studies, risks relating to the significant, time-consuming and
costly research, development, pre-clinical studies, clinical testing
and regulatory approval for any products that we may develop
independently or in connection with Discovery's collaboration
arrangements, and risks relating to the development of competing
therapies and/or technologies by other companies. Companies in the
pharmaceutical and biotechnology industries have suffered significant
setbacks in advanced clinical trials, even after obtaining promising
earlier trial results. Data obtained from tests are susceptible to
varying interpretations, which may delay, limit or prevent regulatory
approval. Those associated risks and others are further described in
Discovery's filings with the Securities and Exchange Commission
including the most recent reports on Forms 10-K, 10-Q and 8-K, and any
amendments thereto.
Company Contact:
Lisa Caperelli, Investor Relations
(215) 488-9413
Discovery up .45 in premarket announcement. Shares at 3.00 in premarket selling of 289,156 shares. Dow Jones News reports Discovery reached clarity with FDA on Surfaxin anticipated approval date now Sept. or Oct. 2007.
That's the best answer to date on the future of the shares. I read the 14a and was hazy about the future of them.
It sure makes me feel a whole lot better. There are a lot of bashers out there for there own profit. It's good to see some really good substance maybe it will make the MM's start to own up on their shorts knowing there is only one true direction. Iregardless of the bumps to come the charts show only an upward trend that I feel is going to continue. With bashers like CindyBOOHOO and her basher croonies out of the way investor confidence will rise from pennyland. i am glad to see fccn is even being defended on other boards from the bashers by a few investors who feel strong about there positions. It's a long winding road to dollarland but nothing in life is easy otherwise we'd all be millionaires by now.
According to my Active Imagination, I can see definitive information that tells me I stand a pretty good chance of making a bundle on fccn. On the otherhand cindyBOOHOO I have never seen a picture of you therefore I don't know if this is Cheerleading or a HORROR story waiting to unfold!! I'll stick with fccn and you can have your $1 dollar.
Discovery labs up 9 points today (+3.66%) to close at $2.55 with 484,323 shares traded (above normal volume). Promised news on FDA meeting on Dec. 22 is immenent. News on FDA could cause another buying frenzy like in September of 2006.
I think one thing is very clear that Steven Peacock knows exactly what he is doing. Did you notice the part that one area of speciality is cleaning up past SEC filings.
I still think there's going to be a bumpy road ahead with the daytraders buying and selling large chunks so they can take profits. You can't stop it from happening and these guys are pro's.
Steven Peacocks info posted on the 14a:
Interim Chief Executive Officer, Interim President, Interim Chief Compliance Officer, Chief Financial Officer and Chairman of the Board of Directors – Steven Peacock has over thirty years of experience in seeking out and identifying emerging growth investment opportunities, both startup companies and work out assignments and is skilled at analyzing management structure and setting up programs for raising capital. He has working knowledge of taking companies through the process of becoming publicly traded, as well as assistance with strategic planning, corporate communications including shareholder relations and internet marketing as well as an extensive background in SEC requirements and filings utilizing broad network of legal, accounting, insurance, Internet technology and public relations affiliates. In addition to his work with and in publicly traded companies, Mr. Peacock has a background in the real estate development industry and in minor league professional sports development, primarily soccer, in both American and European venues. Mr. Peacock has an extensive operating knowledge of the Business Development Company process, having operated the first BDC on the west coast from 1998 to 2000. From 2001 to 2003, Mr. Peacock acted as a consultant for Peak Solutions, a firm offering a variety of consulting, management and financing services to the small business community, both public and private. From 2004 to 2005, Mr. Peacock served as a member of the Board of Directors of BDC Capital, Inc. and as Secretary, Chief Operating Officer and a member of the Board of Directors of CLX Investment Company. Mr. Peacock also served as Chief Executive Officer and Chief Financial Officer of Entertainment Capital Corporation from 2005 to 2006. From 2004 to present, Mr. Peacock has served as managing partner of Javelin Advisory Group, Inc., a business consulting company located in Temecula, California with the core focus of assisting businesses with a number of vital services, which include bringing businesses into compliance with SEC requirements, assisting in the raising of necessary capital, evaluating potential acquisitions and providing management expertise.
Here is the direct link to the 14a filing on the fccn websight. http://www.secinfo.com/$/SEC/Registrant.asp?CIK=1160598
the only dates was february 28 and that was when they said that all delinquent filings would be completed by.
I could only find the filing on the fccn websight. I read the whole thing, I agree that it is good news and it states all of the delinquent filings will be complete by the end of february. It looks to me they are going in a high gear... Nobody would fill out that much paperwork for no reason, it is more than obvious that bigger better things are about to happen. I had difficulty with the reading on Golden Gate but one thing was clear to me and that the board has the shares and the voting right and Golden Gate does not and that is good news to me.
What kind of effect will this have on fccn in the next few days and do you think the PR monday is about the fact they have made this filing?
It's just amazing yesterday nearly 500,000 shares and today dead as a door nail. I think it tells you there are a lot of people sitting on this and just are waiting for something good to happen. I think they all want to own this at .02. It seems to be the golden number. The days it hits that number is the day it does a ton of volume. By the way I did notice the "e".